[10] This is proving to be one of the biggest upsides to GLP-1 treatment
Emerging preclinical data suggests it supports extracellular matrix remodeling and anti-inflammatory signaling relevant to intestinal tissue, but it is not as gut-specific in the literature as BPC-157 or KPV
Most Medicare beneficiaries can take advantage of the new benefit simply by going to their health care providers who will determine whether they meet the medical criteria for getting the medications for $50 a month, regardless of income
As a precaution, current guidelines recommend stopping GLP-1 medications at least one to two months before attempting conception, whether trying naturally or through fertility treatment
While no head-to-head trials have compared GLP-1 drugs specifically for migraine outcomes, we can draw some inferences from their pharmacological profiles and side effect data
All that remains to be seen, and an absolute benefit of 1.5 per 100 people treated is certainly nothing to write home about